Bayer


Still expensive, but a solution is within reach

08/10/19 -"According the press, an out of court settlement for all Glyphosat-based cases seems now to be on Mr Baumann's agenda. Having lost the three original cases in the US, the idea of settling all of them ..."

Pages
64
Language
English
Published on
08/10/19
You may also be interested by these reports :
18/10/19
Roche’s Q3 19 sales growth of 13% CER is the highest quarterly growth in the last eight years. In oncology, the newer drugs have clearly taken over ...

17/10/19
Bulls have been in complete control of Faes Farma (Reduce, Spain) since the start of 2019. While solid Q4 18 results, fuelled by Bilastine (c.24% of ...

17/10/19
The acquisition of RA pharmaceuticals is expected to be margin-dilutive in the short/mid-term as UCB would be required to invest heavily in the ...

17/10/19
UCB has broadened its neuromuscular portfolio with the €2.2bn acquisition of RA pharmaceuticals – blockbuster potential drug, Zilucoplan (expected ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO